<DOC>
	<DOCNO>NCT02887885</DOCNO>
	<brief_summary>Sustainability vaginal ultra-low dose estrogen therapy postmenopausal woman</brief_summary>
	<brief_title>Sustainability Vaginal Estrogen Therapy Postmenopausal Women</brief_title>
	<detailed_description>Within trial 50 postmenopausal woman receive vaginal estrogen therapy treatment symptomatic vaginal atrophy . The sustainability vaginal estrogen therapy end therapy yet investigate . All participant ask come follow 7 visit . - Visit 1 : Standard Gynecological examination ; Inclusion exclusion criterion check - Visit 2 : Handing Gynoflor ( estrogen ) 6 week treatment . - Visit 3 ( Study Start ) : After use vaginal estrogen 6 week , vaginal swap do measure vaginal maturation index ( VMI ) . The participant also receive questionnaire define subjective parameter . The parameter measure visit 1 count reference . The estrogen therapy sustain . - Visit 4-7 : Measuring VMI hand questionnaire define subjective parameter .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Postmenopausal woman ( last menstrual period 12 month ago undergone bilateral ovariectomy ) Age ≥ 18 year Diagnosis moderate severe vaginal atrophy screen visit VMI &lt; 40 % vaginal pH &gt; 5 At least one subjective symptom vaginal atrophy ( dryness , pain/burning sensation , pruritus , discharge , dyspareunia ) relate score ≥ 65 visual analogue scale ( VAS ) Indication vaginal treatment Gynoflor® ( 100 million viable L. acidophilus KS 400 estriol 30 mcg per application ) 6 week symptomatic vaginal atrophy menopause : 1 vaginal tablet daily 12 day , follow 3 vaginal tablet per week maintenance therapy ( MondayWednesdayFriday ) . Informed consent document signature Administration form oral/transdermal hormone therapy ( HT ) selective estrogen receptor modulators ( SERM ) phytoestrogens within 2 month prior entry study . Any use overthecounter vaginal product within 1 week prior entry study . Known hypersensitivity allergy investigational product Estrogen dependent malignancy Undiagnosed genital bleeding Active thromboembolism Active vulvovaginal Candidiasis , Trichomonas vaginitis bacterial vaginitis base light microscopy vaginal secretion , vaginal pH , whiff test KOH preparation Active sexually transmit infection ( STI ) include herpes simplex viral infection , gonorrhoea Chlamydia . Active urinary tract infection . Use antiinfectives Pessaryusers Immunocompromised patient include human immunodeficiency viral infection , chronic glucocorticoid use active treatment immunosuppressive agent Severe liver and/or kidney disease Diabetes mellitus Polyneuropathy Skin disease , e.g . lichen planus , lichen sclerosus , contact dermatitis Known suspect noncompliance , drug alcohol abuse Inability follow procedure study , e.g . due language problem , psychological disorder , dementia , etc . participant , Participation another study investigational drug within 30 day precede present study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>